What is the clinical evidence from this study?

Study design: Review. Population: Atrial Fibrillation. Intervention: K2P channel modulators.

What question did this study set out to answer?

To examine the physiological regulation of two-pore domain potassium (K2P) channels in atrial tissue and evaluate pharmacological modulators targeting these channels for atrial fibrillation therapy.

November 22, 2022Frontiers in Bioscience-ScholarOpen Access

Unraveling the Role of K2P Channels in Atrial Fibrillation

View Full Paper

Ask AI

Bookmark

Key result

Atrial-specific two-pore domain potassium (K2P) channels are dysregulated in atrial fibrillation, and their pharmacological modulation represents a promising novel therapeutic approach.

Why the study?

Available antiarrhythmic drugs often fail as AF progresses, creating a need to identify new therapeutic targets such as atrial-specific K2P channels and effective pharmacological modulators.

Key Points

To examine the physiological regulation of two-pore domain potassium (K2P) channels in atrial tissue and evaluate pharmacological modulators targeting these channels for atrial fibrillation therapy.
Narrative review of structural and electro-mechanical remodeling mechanisms driving the transition from paroxysmal to persistent atrial fibrillation.
Evaluation of atrial-specific K2P background potassium channel subtypes (TWIK-1, TREK-1, TASK-1, TASK-2, TASK-3) and their known pharmacological openers, activators, and blockers.
K2P channels constitute the background K+ current (IK2P) that controls atrial cardiomyocyte excitability without directly affecting ventricular electrophysiology.
Expression of TWIK-1, TREK-1, TASK-1, TASK-2, and TASK-3 subunits is dysregulated during the progression of atrial fibrillation.
Pharmacological modulation of TASK and TREK channels shows potential to restore sinus rhythm while avoiding adverse ventricular side effects common to traditional antiarrhythmic agents.

Structured PICO

Population

Patients with atrial fibrillation (AF)

Intervention

K2P channel pharmacological modulators (openers, activators, and blockers targeting TWIK-1, TREK-1, TASK-1, TASK-2, and TASK-3)

Atrial specific two-pore domain K+ channels (K2P) are dysregulated in atrial fibrillation and emerge as promising novel therapeutic targets to treat persistent or chronic AF while avoiding ventricular side effects.

Limitations

Many TASK modulators lack selectivity for specific subunits due to high homology.
TASK-1 channel blockers may cause adverse effects on the pulmonary vasculature, such as increased pulmonary arterial pressure.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Novel AF remodeling insights may inform targeted therapies; leaves open validation in prospective trials.

Cite This Study

Gema Mondéjar‐Parreño (2022) conducted a review in Atrial Fibrillation. K2P channel modulators was evaluated. Atrial-specific two-pore domain potassium (K2P) channels are dysregulated in atrial fibrillation, and their pharmacological modulation represents a promising novel therapeutic approach.

synapsesocial.com/papers/6a7ca5fa7418813c518ce5c4 https://doi.org/10.31083/j.fbs1404031

Topics

Persistent AF management Atrial fibrillation Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Unraveling the Role of K2P Channels in Atrial Fibrillation

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Topics

Unraveling the Role of K2P Channels in Atrial Fibrillation

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider